Bajaj Finance stock gains as company launches QIP, sets floor price for Rs 8,800 crore fundraise
Sources had previously told CNBC-TV18 that Bajaj Finance is likely to raise up to Rs 18,800 crore via QIP. The indicative price for the fundraise is likely to be at 4 percent discount to current market price.
Sources had previously told CNBC-TV18 that Bajaj Finance is likely to raise up to Rs 18,800 crore via QIP. The indicative price for the fundraise is likely to be at 4 percent discount to current market price. Sources had previously told CNBC-TV18 that Bajaj Finance is likely to raise up to Rs 18,800 crore via QIP. The indicative price for the fundraise is likely to be at 4 percent discount to current market price. Moneycontrol Latest News Read More
Sources had previously told CNBC-TV18 that Bajaj Finance is likely to raise up to Rs 18,800 crore via QIP. The indicative price for the fundraise is likely to be at 4 percent discount to current market price.
Sobha shares crumble 5% after higher costs drag Q2 net profit down
The higher expenses in the Q2 were mainly due to land purchase costs which dragged Q2 profit growth for Sobha downwards.
The higher expenses in the Q2 were mainly due to land purchase costs which dragged Q2 profit growth for Sobha downwards. The higher expenses in the Q2 were mainly due to land purchase costs which dragged Q2 profit growth for Sobha downwards. Moneycontrol Latest News Read More
The higher expenses in the Q2 were mainly due to land purchase costs which dragged Q2 profit growth for Sobha downwards.
Gland Pharma soars 5% on in-line Q2 results; should buy, hold or sell the stock?
Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies.
Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies. Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies. Moneycontrol Latest News Read More
Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies.
English 
हिन्दी